A polymerization process controls poly-α-glutamic acid molecular weight using specific initiators and solvents.
An RGD motif peptide composition targets platelet GPIIb/IIIa receptors to dissolve preformed thrombi.
Stable phosphohistidine analogues enable specific antibody production, resolving acid lability bottlenecks in residue analysis.
A long-acting GLP-1/GIP dual agonist polypeptide combines incretin pathways to enhance metabolic control.